Abstract
Motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are neurodegenerative diseases, which cause progressive paralysis and premature death in affected adults and children. The treatment rational for these diseases is to halt or delay the degeneration of motor neurons but to date there are no effective drugs. This may however change with recent advances in gene therapy using lentiviral vectors. These vectors can transfer genes to motor neurons with high efficiency and give long term expression. One of these vector systems, based on the equine infectious anaemia virus (EIAV), can insert genes into the cells of the central nervous system after remote delivery including delivery into the muscle by exploiting retrograde transport pathways. This opens up the exciting possibity of rescuing the denervation of key muscle groups in patients by simple injections of these neurotropic lentiviral vectors into the muscle. This review will describe the general features of lentiviral vectors derived from the EIAV. It will then describe some key examples of gene transfer and genetic correction in animal models of motor neuron disease. The prospects for the clinical evaluation of lentiviral vectors for the treatment of human motor neuron disease will be outlined.
Keywords: eiav, motor neuron, motor neuron diseases, als, sma, ientiviral, gene therapy
Current Gene Therapy
Title: Non-Primate EIAV-Based Lentiviral Vectors as Gene Delivery System for Motor Neuron Diseases
Volume: 4 Issue: 3
Author(s): M. Azzouz and N. Mazarakis
Affiliation:
Keywords: eiav, motor neuron, motor neuron diseases, als, sma, ientiviral, gene therapy
Abstract: Motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are neurodegenerative diseases, which cause progressive paralysis and premature death in affected adults and children. The treatment rational for these diseases is to halt or delay the degeneration of motor neurons but to date there are no effective drugs. This may however change with recent advances in gene therapy using lentiviral vectors. These vectors can transfer genes to motor neurons with high efficiency and give long term expression. One of these vector systems, based on the equine infectious anaemia virus (EIAV), can insert genes into the cells of the central nervous system after remote delivery including delivery into the muscle by exploiting retrograde transport pathways. This opens up the exciting possibity of rescuing the denervation of key muscle groups in patients by simple injections of these neurotropic lentiviral vectors into the muscle. This review will describe the general features of lentiviral vectors derived from the EIAV. It will then describe some key examples of gene transfer and genetic correction in animal models of motor neuron disease. The prospects for the clinical evaluation of lentiviral vectors for the treatment of human motor neuron disease will be outlined.
Export Options
About this article
Cite this article as:
Azzouz M. and Mazarakis N., Non-Primate EIAV-Based Lentiviral Vectors as Gene Delivery System for Motor Neuron Diseases, Current Gene Therapy 2004; 4 (3) . https://dx.doi.org/10.2174/1566523043346291
DOI https://dx.doi.org/10.2174/1566523043346291 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Mammalian Tachykinin Ligand-Receptor System: An Emerging Target for Central Neurological Disorders
CNS & Neurological Disorders - Drug Targets Subject Index To Volume 6
Current Molecular Medicine Aging and Proteins: What Does Proteostasis Have to Do with Age?
Current Molecular Medicine Extrasynaptic GABA<sub>A</sub> Receptors in the Brainstem and Spinal Cord: Structure and Function
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Aging Science NMDA Receptor Antagonists as Antidepressant and Antidementia Drugs: Recent Developments and Future Prospects
Current Medicinal Chemistry - Central Nervous System Agents Neuroprotection for Amyotrophic Lateral Sclerosis: Role of Stem Cells, Growth Factors, and Gene Therapy
Central Nervous System Agents in Medicinal Chemistry Bioenergetics and Mitochondrial Dysfunction in Aging: Recent Insights for a Therapeutical Approach
Current Pharmaceutical Design Protein Aggregation in Neurodegenerative Diseases: Insights from Computational Analyses
Current Bioinformatics Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Central Nervous System Agents in Medicinal Chemistry Neurodegenerative Disorders and the Current State, Pathophysiology, and Management of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Is the Cytoskeleton an Intracellular Receptor for Adrenomedullin and PAMP?
Current Protein & Peptide Science Cell-Penetrating Peptide Technology to Deliver Chaperones and Associated Factors in Diseases and Basic Research
Current Pharmaceutical Biotechnology Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Special Issue on Stem Cells: An Introduction from the Guest Editor
Current Neurovascular Research Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders
Current Drug Therapy Stem Cells: In Sickness and in Health
Current Stem Cell Research & Therapy Clinical Applications of Myostatin Inhibitors for Neuromuscular Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Synthetic Cannabinoid Receptor Agonists and Antagonists: Implication in CNS Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair
CNS & Neurological Disorders - Drug Targets